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Today, there exists no effective treatment for hepa­
tic failure. Current practices are for conservative and 
general treatment, usually providing only temporary, sympto­
matic relief or general support (1) .
The need is not necessarily to replace the liver.
The liver is the only organ, with the possible exception of 
the skin, which can completely regenerate into a functional 
organ. As an example, rat liver, when excised to 30% of its' 
original size, will completely regenerate in a few days (2). 
Because of the essential functions of the liver, a no-load 
period for regeneration after disease or damage is impossible 
(3). Therefore, the real need is in an assist device for the 
liver, to allow it adequate time to recover.
Detoxif ication
During liver failure, many of the substances typically 
produced by the liver can be substituted by intravenous in­
jections. Many substances that provide a regulatory function
can be monitored and substituted for appropriately. Today, 
the only function of the liver that can neither be supported 
nor substituted is that of detoxification (4). As toxins 
build up in the body, they inhibit the enzymes which deal in 
energy, regeneration, synthesis, and so on. Thus, liver 
disease is often characterized by a descending spiral of 
liver efficiency, ending in hepatic coma and death (5). Be­
cause of the importance of detoxification, most attempted 
liver assists deal in the removal or inactivation of toxic 
substances.
Hemodialysis
Hemodialysis is probably the most acceptable manner 
of hepatic assist today (6,7). Toxins are removed from the 
blood by a concentration gradient across a membrane. This 
membrane could be synthetic or biological, such as the peri­
toneum. Use of hemodialysis as a means of hepatic assist was 
first performed by Kiley, et al. (8). The lack of selectivity 
they experienced using hemodialysis has been compensated for 
by many years of research. Still, this manner of detoxifica­
tion falls short in removing higher molecular weight toxins. 
(The metabolites that accumulate in acute liver failure range 
up to 5000 in molecular weight (9,10)). Opolon, ^  a^. (11,12) 
feel they have met this problem with a new polyacrylonitrile 
(PAN) dialyzing membrane that can handle higher molecular 
weight compounds. However, with what is known about detoxi­
fication, it is unlikely that hemodialysis will be effective
in any form against lipid soluble toxins or toxins bound 
tightly to proteins. Further, there are difficulties with 
the onset of severe hypotension (13-15), hypothermia (16), 
and changes in the blood picture (17-20).
Chemical Adsorbents
An area becoming increasingly more popular is that 
of chemical adsorbents. Rosenbaum (21-24) has noted selec­
tive removal of some compounds in lethal drug intoxication 
cases using a resin adsorption column. Willson (25-28) has 
experimented with charged and uncharged ion exchange resins 
on dogs. Resin hemoperfusion may produce, however, extreme 
hemolysis and lowering of blood platelet counts (29). Weston 
(29-31) found no appreciable lowering of blood platelet loss 
even when he perfused the resin with plasma from an Aminco 
continuous cell-separator in a dog.
Brunner (32) has used a column as the support for 
purified microsomal enzymes. He, however, uses no barrier 
between the enzymes and the blood. While more effective in 
reducing lipid-bound toxins, this system also is open to 
foreign protein attack.
Another very popular sorbent is charcoal. The first
to use charcoal in a blood circulation device was Yatzidis
(33). Many (17,18,19,34,36), including Williams at the 
Liver Unit of King's College Hospital in London (13,14) ,
have reported reversal of hepatic coma using charcoal hemoper­
fusion. The greatest disadvantage of charcoal hemoperfusion is
that it is completely nonspecific. While adsorbing the toxins, 
charcoal will also, for example, adsorb some hormones in the 
blood (37). Another disadvantage is that it is not very bio­
compatible .
Microcells
In order to make the charcoal and other resins more 
biocompatible, Chang devised a method for polymer coating 
these sorbents (35,38-43). These "artificial cells", as they 
are referred to, still do not have a high degree of spe­
cificity. Recently, though, Chang has reported (44) the 
microencapsulation of an oxido-reductase enzyme. This offers 
a great potential in duplicating complejc liver enzyme systems. 
The microcapsules may be injected intraveneously or peritone- 
ally. They may be taken orally or perfused with blood in an 
extracorporeal device. If this is to be used with an enzyme 
system, it must be realized that the enzyme's cofactor and 
regeneration system must be encapsulated in the same cell with 
the enzyme to make an efficient system.
Biological Tissue 
Utilization of biological tissue has been attempted 
by various investigators. The biological systems employed 
include healthy donor blood (45-49) as a transmitter of liver 
function, and liver tissue itself in various forms of pre­
paration (50-55). These techniques have largely met with 
failure, due to preparation and procurement complexities.
difficulties of storage and preservation, and complications 
related to immunology. Although normal liver tissue will not 
replicate successfully ^  vitro (56,57) , various methods of 
liver cell culturing and preservation do exist. Essentially, 
they fall into two categories: (1) blood perfusion of large
surface areas of healthy liver and (2) blood perfusion over 
cultured colonies of hepatomas (58-60) .
In the first case, rapid degradation of catalytic 
properties due to the presence of proteolytic enzymes in the 
tissue is observed, regardless of the method of preparation. 
The second case sidesteps the decay problem by maintaining a 
steady-state vitro cell culture which is then directly 
(or indirectly, across a membrane) perfused with the patient’s 
blood. The concept of continuously exposing one’s blood to 
a thriving, malignant cell culture may not be acceptable 
clinically.
A much more critical form of biological tissue use 
has been in the transplantation of whole livers. Starzl de­
scribed this procedure in 1975 (61) and averages 10-20 such 
operations per year. There is also the technique of liver 
grafting (62-66). In both of these techniques, there is a 
critical matching of tissue to reduce rejection reactions. 
Because of the critical nature of these techniques, their 
use in treatment of hepatic failure is very limited.
Because of the inherent problem in the use of whole 
cells, a logical step would be to use only the catalytic
agent in the cell. This catalytic agent, or enzyme, is highly 
specific with respect to its action. However, it could not 
be injected directly into the body without possibly causing 
allergic reactions and anaphylactic shock (67,68). Further, 
the free enzyme in solution is subject to loss of activity 
due to its' accessability to destructive proteolytic enzymes.
A method for enzyme utilization with more stability is im­
mobilization C69). In addition to stability, the enzyme can 
be easily retrieved for repeated use or isolated in the hemo­
perfusion device. Many researchers (70-77) have attached
phepatic detoxification enzymes to Dacron , porous glass 
beads, sepharose, and other inert matrices. However, with 
most of these detoxification enzymes, there is an associated 
cofactor or cosubstrate such as nicotinamide adenine dinucleo­
tide phosphate (NADP) or uridine diphosphoglucuronic acid 
CüDPGA). These must be maintained in high concentration 
around the enzyme to insure maximum detoxification. Hence, 
a membrane is usually incorporated to retain the cofactor and, 
additionally, repel blood proteins that would give a foreign 
body response to the immobilized enzymes. Even though a 
membrane is used, the cofactor often falls below acceptable 
reaction levels due to leakage.
The problem of supplying adequate amounts of cofactor 
remains dominant (78).
Hybrid Systems
A number of combinations of processes is possible
within a single hepatic assist device. For example/ Yamazaki 
C79/80) has devised an automated system that uses a blood 
separator of hollow fibers, paired with an adsorbent charcoal 
column. A microfilter is incorporated to trap particles of 
charcoal in the plasma leaving this unit. A hollow fiber 
dialyzer is also used. Despite the complexity, the system 
still maintains its shortcomings. For example, the charcoal 
is nonspecific and will not detoxify lipotoxins or those toxins 
bound tightly to proteins.
Based on the information presented in this chapter,
I have developed a similar hybrid system. It consists of a 
plasma separator, a matrix bound enzyme reactor, a mixer, a 
semi-permeable membrane for separation of reactor from plasma 
and, most important, a macromolecule bound cofactor. In the 
following chapters, the proposed system will be presented in 
more detail, as well as its advantages over other systems 
proposed up to now.
CHAPTER II 
COFACTOR RETENTION
The most troublesome portion of any microsomal oxi­
dative enzyme detoxification system, as mentioned in Chapter 
I, is the retention of the cofactors within the enzyme reactor. 
This retention serves two purposes : to prevent the cofactor
from attaining potentially toxic levels in the body and to 
maintain the cofactor at a concentration that will allow 
optimum reaction conditions. It should be understood that 
not all cofactors are considered harmful at high concentra­
tions. Uridine-5-diphosphoglucuronic acid (UDPGA) is a good 
example of this (81).
Nicotinamide adenine dinucleotide, NAD, and its phos­
phate, NADP, however, cause severe vasodepression in test 
animals at dosages as low as 50yg per kilogram body weight 
182).
The manners in which these cofactors might be retained 
have been reviewed elsewhere (83), but three basic techniques 
may be noted:
1) retention by low molecular weight cut-off 
membranes
2) retention by the cofactor's ionic charge, and
8
3) retention by increased molecular weight of the 
cofactor.
Low molecular weight cut-off serves only to retard the per­
meation of the substrates and products of higher molecular 
weight. Therefore, we began studies to retain NADP'*’ by an 
ionic charge. Ionic charge retention was investigated by 
Hare (82) of this laboratory and reinvestigated by Wills (83). 
Various membranes were used, including PVC. The charge was 
incorporated onto the membrane by alignment of the dipoles 
at a temperature above the glass transition point in an 
electric field (see Figure 1). This was followed by cooling 
the membrane while still in the field. This method proved 
to be ineffective. As seen in Figure 2, increased agitation 
decreases diffusional limitations (top curve), but also de­
creases effectiveness of the charge gradient and reduces the 
NADP retention (bottom curve). We then investigated the technique 
of retention by macromolecule attachment to the cofactor.
Many different macromolecules have been attached to 
the cofactor, (84-95); but for NADPH, these techniques have 
had only limited effectiveness. Attempts in this laboratory 
were made to couple succinylated NADP to polyethyleneimine 
(PEI) by a modification of the method of Wykes (86,93) for 
NAD. This proved unproductive and our reaction rates were 
very low, probably because of steric hindrances. Normally, 
a macromolecule of 40-50,000 MW is attached to a cofactor of 
500-1000 MW. This complex is bulky, making diffusion a
FIGURE 1
ELECTRET FORMATION
Membrane electrets are formed by heating the 
polymer to a temperature above the glass 
transistion point and applying a field to the 
membrane as it cools. The heterocharge is 
the realignment of the dipoles. The homocharge 
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The reduced effectiveness of the permanent 
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limiting factor. Further, this spreads the "active" sites 
over a larger molecule. Therefore, we felt that perhaps a 
significantly smaller macromolecule might prove to be more 
effective. Following a modification of the procedure of 
Yamazaki, et al. C96), we attached poly-L-lysine hydrobromide 
CMW 2300) to NADP (MW 800) to form a complex of molecular 
weight approximately 3100, 10,000 if saturated.
In Figure 3, the proposed structure of poly-L-lysine 
succinyl NADP (PL-SNP) is shown. The succinic anhydride is 
used as a spacer group, attached to the a amino end of the 
poly-amino acid. Note that possible binding at the e posi­
tions is being investigated. Not only did this "enlarged"
NADP work with the complex MFMF oxidase enzyme (see Figure 4), 
it gave activities of up to 100% that of pure NADP. A graph 
of this is shown in Figure 5. The y axis represents the reac­
tion rate of the PL-SNP divided by the reaction rate for a 
pre-set quantity of NADPH (6OX of a O.OIM solution). The x- 
axis denotes varying quantities of a 1.0 mg/ml H^O solution 
of PL-SNP.
Therefore, some headway was made into the cofactor 
retention problem, at least for NADP/H. It then became 




PROPOSED STRUCTURE OF PL-SNP
This is the proposed structure of poly-L- 
lysine succinyl amino group. Attachment 
at the e positions is not shown but is 
assumed to be possible. The "R" group 
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FIGURE 4
PLSNP WITH MFMF OXIDASE
PLSNPH is shown reacting with N, N-dime- 
thylaniline (model toxin) in the presence 
of MFMF oxidase enzyme. Also, a regeneration 
system is shown for maximizing PL-SNPH.
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FIGURE 5
RELATIVE RATE OF PL-SNP ACTIVITY
The initial reaction rate for PL-SNP is 
divided by the rate for pure NADPH in the 
same reaction. The PL-SNP was capable of 
giving in excess of 95% the activity of 
pure NADPH. The X unit at the base of the 
figure represents microliters of a 1 mg/ml 
solution of the PL-SNP analogue. This is 
used as the exact molecular weight of the 
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RESULTS
Equilibrium
An attempt was made to evaluate where the equilibrium 
point for formation of reduced PL-SNP lay. The enzyme, 6- 
phosphogluconolactonase, was used to drive the reaction of 
glucose-6-phosphate (G6P), PL-SNP, and glucose-6-phosphate 
dehydrogenase (G6PD) to completion as shown below:
PL-SNP + G6P — — — > PL-SNPH + 6-phosphogluconolactone 
PL-SNPH + 6-phosphogluconate
Adsorption at 340 nanometers was observed as lactonase 
was added to the reaction mix (Figure 6). This did not work 
as either the equilibrium was already far to completion or 
the lactonase was impure. Further study was discontinued.
Binding
Several different techniques were attempted to deter­
mine the degree of binding. As shown in the outline that 
follows, the first attempts were made using known quantities 
of polylysine hydrobromide and NADP. The mixture from the 
synthesis reaction (see Chapter IV) was dialyzed. The amount 
of NADP that was in the dialysate was calculated by its* 
extinction coefficient. This gave ratios of binding of NADP 
to PL-HBr of 3.9 and 2.6.
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FIGURE 6
ADSORPTION AT 340 nitt USING LACTONASE
The adsorption curve at 340 nanometers showed 
no increase, indicating no further production 
of PL-SNPH, upon addition of lactonase. See 
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The next attempt was to purify the PL-SNP formed 
using a liquid chromatography column. The sample was 
collected and the PL-HBr moiety was analyzed by the biuret 
method. The NADP moiety was analyzed spectrophotometrically 
at 260 nanometers. This gave a ratio of 5.2. In the final 
technique, the sample was column purified as above. A dry 
weight was taken. The sample was brought up in a known 
quantity of distilled water and its NADP quantity determined. 
This weight was subtracted from the total dry weight. The 
remaining weight was assumed to be all PL-HBr. This last 
method yielded 1.67 moles of NADP per mole of PL-HBr.
It is possible that these variations were a function 
of small differences in technique for each preparation. The 
likelihood exists that this polyamino acid will not be used 
as the ultimate macromolecule for binding because of its 
potential antigenic properties. Therefore,' further studies 
to determine the NADPH/macromolecule ratio were postponed.
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OUTLINE
A. Dialysis Purified 
1. known quantities
a) 25 mg removed of NADP (ext. coeff.)
53 mg remaining of NADP
53 mg = 7.13 X 10“^moles NADP
743 mg/mmole
b) 42.2 mg PL-HBr starting
42.2 = 1.84 X 10“  ̂moles PL-HBr
2300 mg/mmole
c) 7.13 = 3.9 moles NADP
1.84 mole PL-HBr
known quantités
a) 35.16 mg NADP removed 
6 7.21 mg NADP remaining
67.21 = 9.05 X 10"5 moles NADP
743
b) 80 mg PL-HBr starting
-580 = 3.48 X 10 moles PL-HBr
2300
c) 9.05 = 2.6 moles NADP
3.48 moles PL-HBr
B. Column Purified
1. protein and ext. coeff.
a) 0.375 mg protein (PL-HBr) (from biuret)
0.375 mg = 1.63 X 10“^moles PL-HBr
2300 mg/mmole
b) 0.625 mg NADP (ext. coeff.)
0.625 = 8.41 X 10"^moles NADP
743
c) 8.41 = 5.2 moles NADP
1.6 3 moles PL-HBr
2. dry weight and ext. coeff.
a) conc. = abs._______ = 0.612 = 23.5^  mole
(f)(L) (2.6X10^) liter
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23.5 X 10"3 liter = 23.5 X 10“  ̂moles NADP
b) 23.5 n moles X 743 = 17.46 X 10“® gm NADP
50.0 - 17.46 = 32.54 X 10*”̂  gm PL-HBr remaining
<=> = 14.15 nmoles PL-HBr




The design that I propose consists of 3 units; the 
blood separator, the detoxification device, including a 
semi-permeable membrane, and the mixer. In this chapter, I 
would like to first briefly describe how the overall system 
works. I will then give more detail for each unit.
In Figure 7, we see the proposed overall design.
Blood containing toxins is continuously taken from the patient 
and fed to a blood separator. This device essentially splits 
the whole blood into two fractions: plasma, about 50% by
volume, and the remaining components, about 50% by volume.
The plasma with the toxins is continuously shunted to a de­
toxification unit. Here the toxins are inactivated and, to­
gether with the plasma, sent to the mixer, then back to the 
patient.
This design can also incorporate additional units, 
for instance, a charcoal perfusion system for adsorbing endo­
toxins, such as lipopolysaccharides (LPS)(97). This unit 
might be added after the detoxification unit and would remove 
LPS and some of the more water-soluble metabolites formed in 




Blood containing toxins is continuously 
taken from the patient and fed to a blood 
centrifuge. This device essentially splits 
the blood into plasma and RBC's. The plasma 
with toxin is continuously shunted to the 
detoxification unit. Here the toxins are 
inactivated and together with the plasma, 













S e p a r a t o r
In fact/ if the patient were suffering endotoxin shock, the 
removal of chemical toxins would probably have little effect 
on survival.
Continuous flow rates for this design will vary, de­
pending on a number of parameters related to its application. 
All of the available area of the semi-permeable membrane will 
not be used for compound transfer if the flow is too slow.
Very high flow rates will cause shearing and/or stressing of 
the blood and may cause coagulation problems (98). The flow 
rate limits will be in the area of 60-200 mililiters/minute.
In order to avoid unnecessary stresses to the body, 
the environment within the assist device should approximate 
that of the body. The pH should be 7.2-7.4. The system 
should be primed with physiological saline and the tempera­
ture kept between 34 and 38®C. For such a system in use, it 
would be advisable to have frequent hematocrit and blood 
chemistry checks.
Blood Separator
The importance of the removal of blood formed elements 
in an hepatic assist device has been demonstrated with the 
use of micropore filters. Further, the advantages of working 
with blood plasma rather than whole blood has been outlined 
very well by Yamazaki, et al. (79,80). Briefly, there are 
four distinct advantages to working with plasma;
1) the toxins are going to be in the plasma 
fraction,
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2) use of only the plasma lessens deposition on 
the membrane surface of other blood components,
3) the working fluid volume is reduced, on the 
average, by a minimum of 40%, and
4) allowances do not have to be made for shear on 
blood elements such as red and white blood cells.
If the system is to be continuous, as in dialysis, 
it must contain a continuous blood separator. This may be 
a blood filter with a semipermeable membrane or a centrifuge. 
In the past, continuous centrifugation has always required 
that the components flow past rotating seals while being 
pumped in or out. Even the best of these rotating seals 
tend to lyse the red blood cells (RBC's). Just recently, 
however, a continuous flow centrifuge has been designed which 
contains uninterrupted tubing with an anti-twisting mechanism, 
instead of rotating seals (99). When applied to blood separa­
tion, continuous seal-less centrifuges have demonstrated con­
stant plasma flow rates with negligible platelet injury and 
little or no evidence of hemolysis for 12-hour periods (99).
Some considerations for choosing between continuous 
seal-less centrifuges and blood filters are:
1) The centrifuge gives 80 ml/min. of plasma while 
the blood filter gives only 40 ml/min. (99,100).
2) The filter undergoes filtrate flux reduction due 
to platelet deposition on the membrane (101).
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3 \ The latest spiral designs in seal-less centri­
fuges, allow other selected blood fractions to 
be available for alteration. It is projected 
that not only will the white blood cells (WBC's) 
be available, but selected leucocytes, such as 
granulocytes, may be chosen.
4) Seal-less blood centrifuges are expensive and not 
readily available.
5) Blood filters are simple, inexpensive and readily 
available.
The blood separator is a good example of how the de­
sign of an hepatic assist device can change with application. 
If higher plasma flow rates or separation of other blood 
fractions are not necessary for detoxification, then a blood 
filter might be advisable over a blood centrifuge.
Mixer
The need for a mixer has not been established, and 
further study is suggested in Chapter 5. The mixer is 
responsible for blending all separated parts of the blood 
into a homogeneous mixture. This is a relatively simple 
process, but there must be a minimization of shear on the 
cellular components. A typical mode of mixing is to dis­
charge the components into a holding tank of small volume, 
approximately 100 ml, and stir with paddles. Baffles may 
be placed in the tank to increase turbulence, which assists 
in mixing. With paddles, or any moving object within the
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tank, there will be shear. The amount of shear will depend 
on the configuration of the paddles and also on the speed at 
which they are turned.
Another, less complicated, mixing tank is shown in 
Figure 8. As shown, the plasma, RBC's, and remaining fractions 
are discharged into the top of the tank but below the liquid 
level. The plasma is discharged vertically while the RBC's are 
discharged horizontally. Note that the horizontal nozzle is 
flared and mid-way between the center and the side of the 
tank. The momentum of the fractions as they are pumped into 
the tank is used to create mixing. The flared nozzle also 
creates a back-mix. The mixture is swirled as gravity, a 
small force, actually, settles the mixture. At or near the 
bottom of the tank, the homogeneous mixture is removed to 
the patient. The second configuration contains fewer shear- 
producing parts and converts the energy from pumping into 
mixing energy for the components.
Detoxification Unit 
The most complicated unit of the entire design is 
the detoxification system. As can be seen in Figure 9, it 
consists of three chambers.
"Walk-through" of the unit. How this unit works 
might best be explained by following the reaction of a model 
compound, N,N-dimethylaniline (DMA), through the system at 
steady state conditions.
The DMA toxin enters chamber 1 with the blood plasma. 




As shown, the plasma, RBC's, and remaining 
fractions are discharged into the top of the 
tank but below the liquid level. The plasma 
is discharged vertically while the RBC's are 
discharged horizontally. Note that the hori­
zontal nozzle is flared and mid-way between 
the center and the side of the tank. The 
momentum of the fractions as they are pumped 
into the tank is used to create mixing. The 
flared nozzle also creates a back-mix. The 
mixture is swirled as gravity, a small force, 
actually, settles the mixture. At or near the 
bottom of the tank, the homogeous mixture is 










■ THE DETOXIFICATION UNIT
Toxin enters with the plasma into chamber 1 . 
Here it contacts a concentration gradient of 
toxin between chambers 1 and 2 across the 
membrane. In chamber 2 , the toxin is pumped 
to the fluidized bed reactor, chamber 3 .
Here, the toxin is inactivated by the catalytic 
action of the enzymes. The inactivated compound 
is brought back to chamber 2 where a gradient 
of inactivated compound exists opposite to the 
original toxin. The inactivated toxin is taken 
away by the plasma once it enters chamber 1 .
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chambers 1 and 2 . High DMA concentration in chamber 1 
forces the DMA across the semi-permeable membrane into cham­
ber 2 , which contains low concentrations of DMA. From 
chamber 2 , the DMA in plasma is pumped to chamber 3 , 
which is a fluidized bed reactor. In the reactor, there is 
the potential for many different reactions. However, only one 
reaction will be discussed. An explanation of why there is 
such a potential for other reactions will be discussed later 
in the paper. The reaction is:
NADPH + DMA + Og + H* >
NADP* + DMA-oxide + HgO
[1]
The specific enzyme to catalyze this reaction is mixed func­
tion microsomal flavoprotein oxidase, MPMFO, (E.C.1.14.13.8), 
The cofactor involved, nicotinamide adenine dinucleotide 
phosphate (NADP), is very expensive and has therefore been 
regenerated by an additional enzyme system as shown in equa­
tion [2] .
DMA_ . i^NADPH.^ lactone
DMA- 0 ^ ' ^  NADP G6P
Ej [2]
where: = MFMFO ; Eg = G6PD
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The DMA has now been changed to DMA-oxide in the reactor and 
is returned to chamber 2 . A concentration gradient of 
DMA-0 is set up in the opposite direction of that of DMA.
The DMA-0 permeates across the semi-permeable membrane, to the 
plasma in chamber 1. From there it exits the unit to the mixer.
Chamber 1 . Chamber 1 must be of a biocompatible 
material because it contacts the plasma. There is a variety 
of materials to choose from: silicone rubber, Teflon, poly­
acrylamides, and so on (102, 103). The most commercially
available is silicon rubber, which goes by the trade name
R RSilastic . A fairly new material, Hydron , is rapidly
becoming popular. It is part of a class of materials known 
as hydrogels. These have shown exceptional biocompatibility, 
particularly when applied to large surface areas (104). The 
actual chamber would probably best be made of glass or alu­
minum coated with the biomaterial on the plasma-contacting 
surfaces.
Semipermeable membrane. The membrane separating cham­
bers 1 and 2 will vary in its specifications as the applica­
tion changes. The function of the membrane is to allow the 
toxins to permeate but retard passage of large molecules, such 
as the blood proteins, which include fibrinogen and albumin, 
into the reaction chamber. It has an additional function, 
retaining the cofactor, which is NADPH in this case, on the 
reaction side of the unit. Retention of the cofactor tends 
to set an upper limit on the molecular weight cut-off of the
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semi-permeable membrane. This limit will be discussed further 
in the cofactor section of the paper. Part of the aim of the 
detoxification unit is to inactivate "middle molecular weight" 
toxins. These molecules are often not dealt with in dialysis 
(9,10). Two membranes that have worked fairly well in our 
system are Cuprophan (RP-514) and cellulose acetate (AN-69). 
They are also known for acceptable biocompatibility (105).
Care must be taken, however, in using these membranes in dif­
ferent environments. The flux rate across the membrane for 
a compound in distilled water can differ greatly from the 
same compound in saline. This difference is, in part, due 
to different degrees of swelling of the membrane. This in­
dicates another design parameter. Consideration of the con­
centration of the dissolved solutes and the flux of the 
subject toxic compound should influence the selection of the 
membrane used in the unit.
Chamber 2 , and the fluidized bed reactor. Chamber 
2 acts as a small reservoir for the fluidized bed reactor.
The purpose of the reactor is to provide a catalytic bed for 
the reactants involved. The catalytic action is provided 
by specially prepared hepatic enzymes. While not the only 
way to detoxify a compound, these enzymes are the most spe­
cific (106,107). Because of high specificity, side reactions 
are minimized and the potential for creating a new compound 
that is even more toxic than the original toxin is greatly 
reduced. The enzymes may be used in one of two forms: 1)
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free in solution or 2) immobilized on an inert matrix. Which 
form is used again depends on the application of the whole unit. 
In dealing with the MFMFO enzyme, Sofer (106-108) found that 
half-life and thermal stability were increased by over a 
factor of 100 when this enzyme was immobilized on inert glass 
beads. At the same time, however, mass transfer limitations 
to the surface reduced the reaction rate by 10 fold. This same 
trend was found true by Wills (109) when immobilizing liver 
microsomes. However, there is a disadvantage to using free 
microsomes in solution when proteolytic enzymes are available. 
These proteolytic enzymes destroy the detoxifying enzymes. 
Caldwell of this lab (110) has recently compared the reaction 
rates of MFMFO and microsomal enzymes, both immobilized and 
free (Table 1-5). The procedure we used to acquire all rates 
is given in Chapter IV. The immobilization was performed by 
Schiff base likage of the amine-coated glass with glutaral- 
^ehyde., followed by Schiff base linkage of the bound glutaral- 
dehyde with free enzymes or microsomes (109). The upper activity 
limit is 284 nanomoles (n moles) of DMA metabolized per minute 
per milligram of enzyme protein, using a semi-pure MFMFO free 
in solution. The half-life for the enzyme in this reaction 
scheme is approximately 10 minutes. The lower activity end 
is 0.07 n moles of DMA/minute/mg of glass beads, using micro­
somes immobilized as described above, but with a half-life 
of approximately 5+ days. The MFMFO is not available 
commercially and is very expensive. It becomes even more
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TABLE 1
REACTION RATES FOR DIFFERENT ENZYME FORMS 
(See Reference 110)
Maximum Rate
Enzyme Form n moles/min/mg*
Oxidase in Solution 284.2
Hog microsomes in solution 6.9
Dog microsomes in solution 4.2
Dog microsomes immobilized on glass beads 0.07
*mg of protein
This reaction rate is on a per milligram of dry bead basis. 
Determining the mg of protein per mg of dry beads is very 
difficult with microsomes because of the"low amount of protein 


















*The activity is based on 9.2 mg protein per ml of 




















80 .3505 5.982 6.404
80 .3251 6.552
100 .3251 6.077
100 .3429 6.409 6.265
100 .3376 6.310
The activity is based on 51.36 mg of protein per ml 




XTPN Rate a Rate min mg Avg. Rate For Cone.
20 .209 3.028














100 .293 4.239 4.183
100 .274 3.974
*The activity is based on 66.27 mg of protein per ml of 
liquid. The experimental method is given in Chapter IV.
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TABLE 5
DOG MICROSOMES IMMOBILIZED ON BEADS*
XTPN a Wt Beads (mg)
40 .0375 54.90 .06557
60 .0180 53.74 .03219
80 .0250 52.42 .04578
80 .0240 33.80 .06816
100 .0178 33.21 .05139
120 .0250 37.02 .06483
The activity is based on per mg of glass beads basis. The 
amount of protein per mg of glass bead is difficult to 
calculate and is estimated at 20 mg/gm (109). Experimental 
procedure for the above rates is given in Chapter IV.
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expensive if immobilized. The liver microsomes are fairly 
inexpensive and relatively easy to prepare (109). The micro­
somes also allow for a flexibility in reaction control. That 
is, the particular reaction necessary may be dictated by 
merely specifying which cofactor will be available, in solu­
tion, for reaction. This reduces the need to have a specific 
homogeneous enzyme available at any given moment or applica­
tion. The reaction rate is a critical design parameter when 
considered in conjunction with the semi-permeable membrane.
Even though the reaction rate may be 160 n molès/min, the 
flux across the membrane (for a set area) may be only 100 
n moles/min. Obviously, there is variability in design to 
correct such a problem. This again reinforces the philosophy 
that there is no one set design for an hepatic assist device. 
The design will be dictated, for the most part, by its use.
Cofactors. The cofactor problem has already been 
discussed in some detail in Chapter II. The reader is referred 
to that discussion.
Substrates (Toxins). Whether toxins can be detoxified 
with this system will depend on;
1) whether they are small enough to permeate the 
membrane;
2) their solubility in the plasma;
3) if there is a proper cofactor available to allow 
the reaction to take place.
(Note: If liver microsomes are used as the enzyme source,
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there is a fairly good chance that the proper enzyme will be 
available to toxify the particular toxin.) To date, four 
model toxins have been tested. Para-nitrophenol (p~N({)) and 
7-hydroxychlorpromazine (7-OHCPZ) have both been tested using 
microsomes, both free and immobilized, with the cofactor UDPGA 
C109). The specific catalyzing enzyme was UDP-glucuronyl- 
transferase. DMA and ethylmorphine have been tested, using 
free and immobilized oxidase (111), and free and immobilized 
microsomes (110). Again, these are only model toxins used 
to acquire data about the system and are not to be construed 
as the only toxins capable of inactivation. A word should 
also be made here about the term "inactivation". In some 
cases a toxin, particularly a drug toxin, may be inactivated 
by covering the molecule with other chemical groups. These 
groups, such as glucuronic acid from UDPGA, also make the 
molecule more water-soluble, thus making it easier to be 
eliminated from the body with the urine. There are some 
compounds, however, that are not inactivated when run through 
this metabolic scheme. For instance, B-naphthylamine is an 
active carcinogen when N-hydroxylated with MFMFO and NADPH 
tll2). This example is the exception rather than the rule 
and is presented only to emphasize the need for careful selec­
tion of the particular detoxifying system.
Critical Design Parameters 
The application of the hepatic assist device will in 
part dictate its design. The limiting factors and how they
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interact will be discussed next. Some of these parameters 
have already been mentioned. Perhaps, it would be best to 
list them all and discuss each.
Plow Rate. In dealing with flow rate in the design, 
the limiting factors will be the blood separators.
The greater the flow the more membrane surface area 
is used and thus the greater the flux. Of the two 
available sources for blood separation, the seal-less centri­
fuge will provide the highest flow rate. Again, this unit 
is less available and more complicated than the blood filter, 
but can provide approximately twice the flow rate, 80 ml/min 
(100).
Membrane. The semi-permeable membrane plays one of 
the most important roles in the assist device. It must re­
tain the cofactors on the reactor side and the blood proteins 
and macromolecules on the body side. At the same time it 
should provide maximum permeability for the toxin and its 
counter-part the inactivated form. The molecular weight cut­
off, and hence the permeability, will be determined for two 
reasons. One is to maximize the reaction conditions in the 
reactor. The second reason is to keep those cofactors that 
can be harmful out of the body. This becomes a very difficult 
situation when the toxin and the cofactor are approximately 
the same size. One answer, as mentioned previously, is to 
make the cofactor larger. This has been done with NAD? while 
still maintaining reactions rates above 95% (113).
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As with chamber 1 from Figure 9, the membrane will 
also have to be biocompatible, with blood plasma.
Reaction Rate. Two things will dictate which enzyme 
form is to be used: 1) how long the device will be in use,
and 2) which detoxification reaction is to be duplicated. 
Referring to Table 1, if for example, one were to detoxify 
18 mg of DMA in 20 minutes, it would be necessary to use 10 mg 
of pure oxidase with a reaction rate of 284 n moles of DMA/ 
min/mg of enzyme. This, however, would be very expensive, 
require very permeable membranes, and high blood plasma flow 
rates. On the other hand, if the situation is less critical, 
inexpensive immobilized dog microsomes with a reaction rate 
of 0.07 n moles/min/jpg of glass bead could be used. If 10 
grams of beads were used it would take about 13 hours to de­
toxify the same 18 mg of DMA.
Interrelationship of Parameters. One fundamental 
relationship for calculating the membrane area is:
A =  E------  13]
PtCg - V
owhere: A = Area (cm )
F = Flux of toxin (mg/min)
P = Permeability of toxin (cm/min) (Assuming perfect 
mixing on both sides of the membrane and only a 
concentration gradient)
3C = Body toxin concentration (mg/cm )15
= Toxin concentration in the reactor
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Using this relationship, a balance can be set up 
around the detoxification unit. Referring to Figure 10, 
the change with time in the mg quantity of ethylmorphine, 
(EM, model toxin) in the reactor is:
d(EM„) EM^ EM„
= k, - k, EM, [4]dt ''1 ̂ Vg Vn' 3 " R
The change with time of the mg quantity of EM in the blood 
is:
d(EM„) EM EM,
- T  - vf> [=1
where : = P A [6]
kj =. (Act) (Wt^eaag) 171
= = (Mtbeads)
The total change in EM with time is:
where: = volume of reactor (mis)
V_ = volume of blood detoxified (mis)D
P = permeability (as before)
A = area (as before)
Wtj^eads “ quantity of beads used (gms)




■ PARTIAL KINETIC MODEL OF 
DETOXIFICATION UNIT
A model toxin, ethylmorphine (EM) is 
shown permeating from the body (B) into 
the reactor (R) at a rate Once in
the reactor, the EM can either react to 
product at rate k^ or permeate back to
the body at rate k^.
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% K i EM
EM r
^  ProductE M
EM = total quantity of ethylmorphine (mg)
EMg = quantity of ethylmorphine in the body only (mg)
EM„ = quantity of ethylmorphine in the reactor only (mg)
" ~1~M ~ '̂eads"^ X # gm beads (rule of thumb)
With such a scheme, the values of EM_, EM , and EMR J3
can be found by solving equations 4-8 simultaneously. Of 
course, there are certain major assumptions with this such 
as:=
1) a two compartment model only
2) perfect mixing on both sides of the membrane
3) a" average reaction rate (in actuality for long 
periods this would be adjusted to an exponential 
decay)
4) that there is no liver function to assist or 
inhibit the detoxification rate.
However, when programmed correctly on a computer, 
they can be modeled very nicely by varying one parameter 
while the others are fixed. Because of the complex nature 
of the design, it is not feasible to present all the possible 
configurations and their mathematical models here. An example 
is given in Figure 11 illustrating how the toxin level varies 
when different amounts of immobilized microsomes are used. 
Reaction time is 600 minutes. It is clear that a tool exists 




GRAMS OF IMMOBILIZED MICROSOMES
The difference in ethylmorphine concentration is 
shown using different quantities of immobilized 
microsomes. This plot was generated by the com­
puter model on page 51. The reaction time is 
600 minutes. For 100 grams of beads, the cal­
culated quantity of EM passed to the reactor is 
17.97 mg. The experimental value, assuming con­
tinuous maximum concentration difference (0 con­
centration in the reactor and 250 mg of EM in 
the body) is 18.65 mg. This value should be 
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Preparation of Liver 
The procedure for preparation of the liver used as 
an enzyme source is taken directly from another work by the 
author (109) .
The homogeneous MFMF oxidase enzyme and the hog liver 
microsomes were the gift of Dr. D.M. Ziegler of the Clayton 
Foundation, University of Texas at Austin. They came to our 
laboratories already prepared for use. The exact procedure 
for preparation of hog liver and MFMFO is published elsewhere 
(107) .
Dog liver was obtained through the cooperation of the 
Oklahoma City Animal Shelter. The shelter would inform this 
lab in advance when animals were to be euthanized. This al­
lowed proper holding solutions to be prepared and allowed 
staff to be on hand to perform surgery immediately after the 
animals had been euthanized. Animals were placed in a high 
altitude chamber (the equivalent of 50,000 ft) for 15-20 min. 
After animals had been pronounced dead by shelter technicians, 
the livers were removed, sliced into thin sections, and dropped 
into a cold solution of 0.15 M sucrose/.001 M EDTA. The liver.
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in solution, was then transported to our lab for further 
preparation.
The liver was drained of buffer and put through a 
food and meat chopper (Universal Chopper Division, Union 
Manufacturing Co., Model #1551) at its finest setting, twice. 
During this grinding procedure, chopper and liver remain cold 
(approximately 10°C). The ground liver is then homogenized 
with a tissue grinder (pyrex. Corning #7725), utilizing an 
electric drive (A.H. Thomas Co.). During this homogenizing 
process, the grinding tubes are immersed in an ice bath to 
maintain the liver sample below 10°C. The homogenized liver 
sample is then spun in a Beckman model L2-65B ultracentrifuge 
at 20,000 g for 20 minutes. The pellet, which contained 
connective tissue, cell wall, nuclei, lysosomes, and so on, 
was discarded. The supernatant was respun at 100,000 g for 
1 hour. This time the supernatant, which contained the cyto­
plasme, was discarded. The pellets were brought up in ap­
proximately 50 ml total of cold, 0.01 M potassium phosphate 
buffer CKphos) pH 7.5. This fraction contained the microsomes 
and ribosomes. The mixture was then pulse sonicated (0.20 
sec on, 0.80 sec off) for a total of 300 sec at 200 watts 
by a Sonic cell disrupter (model W-350 from Heat Systems- 
Ultrasonics, Inc.). This procedure was carried out in a 
stirred ice bath. The combination of the ice bath and pulse 
sonication kept the mixture temperature from going over 10*C. 
The sonicated microsome solution was then dialyzed in 15-20 ml
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quantities using #20 Dialyzer Tubing (VWR Scientific) in 
0.01 M Kphos buffer pH 7.5. The dialysis was performed 3 
times for 45 minutes each, using fresh buffer each time.
The microsomes were then respun at 70,000 g for 1 hour. The 
pellets were brought up in a total of approximately 15 ml of 
cold 0.01 M Kphos buffer pH 7.5, giving around 20-30 mg/ml 
protein, and stored in the refrigerator. The supernatant 
was concentrated to 60-70 mg/ml protein in an Amicon Ultra­
filtration cell, model 52, using a PMIO membrane, all of 
which were submerged in an ice bath. The supernatant was 
also stored at approximately 4°C.
Preparation of Immobilized Microsomes
The liver microsomes were used in two forms, bound 
and unbound to glass beads. The unbound microsomes were 
stored on a long-term basis in quantities of 3-5 ml in the 
freezer. Frozen microsomes were slowly thawed and rehomogenized 
in an ice bath before use.
The matrix used for insolubilizing the microsomes was 
glass beads with an alkylamine coating (Pierce Chemical Co. 
Biomaterial Support No. 23650). The technique is quite simple 
(114). One gram of beads is placed in 10 mis of a 2.5% glu- 
taraldehyde solution. This mixture is then placed under vacuum, 
at room temperature, for 30 minutes. The mixture is removed 
from the vacuum and allowed to sit an additional 30 minutes at 
room temperature and pressure. The glutaraldehyde has now 
undergone Schiff base linkage with the amine groups on the
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surface of the beads. The beads are washed several times 
with glass distilled water until the odor of the glutaralde­
hyde is no longer detectable. Two mis of the microsomes are 
added to the beads, a quantity sufficient to cover the sur­
face. This mixture is placed in an ice bath and subjected 
to a vacuum again for 30 minutes. The mixture is removed 
from the vacuum and refrigerated at approximately 10®C at 
room pressure for 4 to 6 hours. The excess microsomes are 
decanted, and the beads are washed 5 or 6 times, with 50 mis 
each time of 0.05 M Kphos buffer, pH 7.4. The beads are then 
stored at 5-10®C under 50 mis of the same buffer.
PL-SNP Preparation 
(As taken from a paper by Wills, et (113)).
Preparation of the PL-SNP was according to a modifi­
cation of the technique of Yamazaki, et a2. (96) for NAD.
Two grams of succinic anhydride were dissolved in 
10 ml of dimethylsulfoxide, followed by the addition of 50 mg 
of NADP. The reaction vessel was covered with Parafilm, mag­
netically stirred, and placed in a 30® water bath for 65 hours. 
As performed by Wykes, et a^. (86,93) , for NAD, the succinyl- 
ated NADP (SN) was then precipitated with acetone. The pre­
cipitate, after being washed throughly with acetone, was set 
aside to dry. The dried SN was brought up in approximately 
10 ml of HgO. Concurrently, 80 mg of poly-L-lysine hydro­
bromide was brought up in approximately 3 ml of HgO, then 
added to the SN. The pH was adjusted to 4.8, followed by
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addition of 300 mg of ethyldimethylaminopropylcarbodiimide 
hydrochloride (EDC). The pH was then readjusted to 4.8. The 
vessel was covered with parafilm and again magnetically stir­
red in a water bath, only this time at 40°C. After 8 hours, 
another 300 mg of EDC was added and the pH adjusted to 5.3.
The reaction was returned to the bath and allowed to run an 
additional 12 hours. The poly-L-lysine-succinyl-NADP (PL-SNP) 
reaction solution was purified by column chromatography using 
an anion exchange packing. The resin used was Dowex-1, 1X2-400, 
chloride form, 2% cross-linked in a column 21 x 1.5 cm. The 
column was eluted with an exponential gradient from 0.0 to
0.1 M HCl at a flow rate of approximately 2 ml/min. The final 
peak, with a retention time of 1 hour and 20 minutes was 
identified as PL-SNP. The PL-SNP mixture was detected at 254 
nra. The proper peak for PL-SNP was determined by an evalua­
tion of polypeptide content and ability to form a detectable 
peak at 340 nm (reduced NADP).
The purified PL-SNP was lyophilized, brought up in a 
few ml of HgO, then re-lyophilized. The yield was approximately 
10 mg of a slightly yellow, feathery compound. The PL-SNP 
was stored at 8°C. Concentration for the assays was 1.0 mg/ml.
Reaction Rate Assays 
(Taken from a paper coauthored by Wills (83))
Reaction rates were determined by observing the uptake 
of dissolved molecular oxygen in a closed system with a typical 




Small scale batch reactions were studied 
with the polarograph. The water jacketed, 
closed system microreactor uses a Clark-type 
oxygen electrode to measure initial reaction 



















electrode (see Figure 12). A typical aqueous reaction medium 
consists of the following: 0.054 M K-phosphate buffer, pH
7.4, enough glucose-6-phosphate dehydrogenase to regenerate 
a minimum of 400 mmoles/min NADP^, 0.5 mM N,N-diemthylaniline,
0.0-0.22 mM NADP"^, and 10 mg of catalyst (MFMF oxidase on glass 
beads). Total reactor volume was 1.6 ml. The solid catalyst 
was prepared in pre-weighed samples of 20 mg each. All reac­
tions were carried out at 37 + 0.01°C, and all buffered reac­
tions at pH 7.4.
Reaction rate was determined by observing the rate 
of dissolved oxygen uptake in the closed system, which is 
itself equal to the rate of product synthesis. The rate of 
oxygen consumption was measured by the electrode coupled to 
a strip chart recorder.
Permeability Studies 
Permeabilities of various compounds through test mem­
branes were measured in specially built reactors (115). The 
reactors were a sandwich of 2 plexiglass pieces and a membrane. 
Each plexiglass piece had a recessed chamber 5 cm in diameter 
and 6 mm deep, with an outer sealing ring of rubber. Each 
chamber contained 2 access ports, 1.5 mm in diameter. During 
testing the reactors were placed in a shaker bath at 37*C.
The shaker bath was a Dubnoff model, set to agitate at 100
J5cycles/min. The membranes of Cuprophan , RP-514, cellulose 
acetate, and AN-69, were a gift of HOSPAL, Inc. (Salt Lake 
City, Utah USA).
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In Table 6, permeabilities for the RP-514 and the 
AN-69 membranes were calculated from experimental data using 
equation [3]. Other permeabilities were found in the litera­
ture (115,116).
Membrane Preparation
(As taken from a paper coauthored by Wills (83))
An isotropic PVC film 6.5 x 6.5 inches is sandwiched
between successive layers of aluminum foil electrodes and
dielectric sheets (Figure 13). Dielectric sheets, also
trimmed to 6.5 x 6.5 inches, consisted of dense, high grade
paper, 8 mis thick. Two dielectrics serve to insulate the
electrodes from the press faces. Another dielectric has been
necessary because of arching which may occur due to minor
imperfections in the polymer film and electrodes accentuated
by the high compressive loads. A third, uncharged aluminum
sheet is also included to assure a smooth mating surface for
both sides of the film. The net effect of the paper dielectric
and foil is to reduce the effective field intensity through
the polymer by approximately 10 times. This was more than
offset by the capacity of the power supply and by the higher
potentials that can be tolerated in this design.
The sandwich is then placed between the cool faces of
2the press, and loads varying from 100 to 700 lb/in applied.
The power supply is set in a voltage limiting mode at 1.0 to 
1.5 Kv, (greater potentials than 1.7 Kv caused arcing through 
the film and dielectric sheets), and the electrodes connected 
to the respective foil tabs on the sandwich. At this point,
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Permeabilities of solutes NADP, PLSNP, EM and DMA at 37®C 
are listed for cuprophans PT-150 and RP-514, and for acry- 
lonitrile RP-AN-69. Permeabilities listed in parenthesis 
for the PT-150 and the AN-69 are based on membrane resis­
tance plots found in the literature (115,116), while others 
for the RP-514 and AN-69 are typical values determined in ex­
perimental studies in our lab. Experimental values were 
found to vary with ionic concentration of the solvent as 





The polymer membrane is shown sandwiched 
between two electrodes. The electrodes 
are isolated from the heated press by di­
electrics. The center foil provides a 















it should be noted which side of the membrane will have the 
desired charge. The potential is allowed to accumulate to 
the set limit, and the individually controlled thermostatic 
heaters are set at the appropriate polarization temperature 
(80®C for PVC, 60®C for cellulose acetate). As the tern- . 
perature increases, data are collected at intervals on 
current voltage, and temperature. During initial stages of 
polarization, data should be taken at 15-second intervals to 
observe rapid changes. The interval can be gradually increased 
to several minutes until current and temperature stabilize 
after one to two hours. At this point, all potential dipole 
alignment has probably taken place, yet the field and heating 
are usually maintained for a total of three hours to assure a 
maximum persistent charge. After this period, the heaters 
are turned off, and forced convection cooling from a large 
blower bring the press faces to room temperature within two 
hours. It is critical that the high voltage potential be 
maintained uninterrupted during this cooling period, as the 
electret will relax in a matter of seconds at high tempera­
tures. . Furthermore, removal of the electret from the press 
even at modest temperatures of 45-50°C results in appreciable 
charge decay. Once the press has cooled completely, the sand­
wich is removed and the electrodes carfully peeled from the 
film. The polarity of the film may be marked directly on the 
film at this time. To assure that no destructive homocharge 
behavior will be present during membrane evaluation, the film 




The design of an hepatic assist and a mathematical 
model have been presented. There remains, however, much 
work before the unit may be tested on an animal. Therefore,
I submit the following recommendations for further research:
1) An evaluation is needed of whether the mixer is 
necessary. Can the two streams be adequately 
mixed if they are simply reinfused into the body?
2) A more rigorous study needs to be made of the 
vasodepressant effects of NADP/H. Will the slow 
infusion of NADP/H be a problem?
3) While suggesting a 50/50 split on the blood 
plasma in the separator, the problem of pumping 
an 80 hemtocrit could be very difficult. There­
fore, a study should be made of pumping high 
hematocrit blood.
4) More parametric data is needed, particularly on a 
larger size unit. A scale-up from the 2-5 ml 
reactors and study is in order.
5) The mathematical model suggested needs to be 
expanded to the whole design and then utilized
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to eliminate the extreme designs which would 
not be feasible to build due to size or cost.
6) Multi-enzyme reactions should be investigated 
for incorporation into the proposed hepatic as­
sist design.
With the completion of the above studies, the testing of the 
device on an animal should be a reality.
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